Neuroleptic malignant syndrome: need for early diagnosis and therapy

J Ayub Med Coll Abbottabad. 2006 Jan-Mar;18(1):17-21.

Abstract

Background: Neuroleptic Malignant Syndrome (NMS) is a medical entity that has received little attention in the clinical settings in Pakistan. The aim of our study was to review the predisposing factors, outcomes and characteristics of in-patients diagnosed with NMS.

Methods: We performed a retrospective chart review of all cases (age >15 years) at a tertiary care center in Karachi between January 01, 1990 and November 30, 2001, diagnosed using ICD 10 coding. Data was collected using a standardized data entry form and statistical analysis was performed using Epi Info 6, Version 6.02.

Results: There were a total of 20 patients diagnosed with NMS (11 male and 9 female) in our study with a mean age of 46.6 +/- 15.9 years. Haloperidol was the most frequently responsible neuroleptic. Of the 18 patients on a neuroleptic, most developed NMS after 8 weeks of therapy. There were 5 mortalities all of which were associated with septic shock. Fourteen patients recovered completely from the episode and did not have any neurologic sequelae.

Conclusions: NMS is an important preventable clinical entity. Early diagnosis and judicious use of antipsychotics is warranted to prevent mortality and heightened morbidity.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antipsychotic Agents / adverse effects*
  • Female
  • Haloperidol / adverse effects*
  • Humans
  • International Classification of Diseases
  • Male
  • Middle Aged
  • Mood Disorders / drug therapy
  • Neuroleptic Malignant Syndrome / diagnosis
  • Neuroleptic Malignant Syndrome / physiopathology*
  • Neuroleptic Malignant Syndrome / therapy
  • Retrospective Studies
  • Schizophrenia / drug therapy
  • Shock, Septic / mortality

Substances

  • Antipsychotic Agents
  • Haloperidol